Intas' arm to make overseas foray next year

Ahmedabad-based Intas Biopharmaceuticals (IBL), a group company of Intas Pharmaceuticals, will launch its first batch of biotech products in the overseas market.

"We will launch our biotech products "� Granulocyte Colony Stimulating Factor (GCSF) and Erythropoietin (EPO)"� in Europe, Australia and the New Zealand by the end of 2008," Mani Iyer, director of IBL, told Business Standard.

Intas Biopharma has lined up an investment of Rs 350 crore for its biotech expansion programme. The company will be investing Rs 100 crore in plasma fractionation plant, Rs 150 in recombinant technology and Rs 100 crore in fractionation. All the investments will be in a phased manner.

According to Iyer, the project on recombinant technology will begin in 2008, while the plasma project will start in July 2008. The company will be funding 50 per cent of the Rs 350-crore project through internal accruals and rest through equity. The company will also be raising Rs 50 crore via private equity.